FIPB clears Mylan proposal Illustrative image – not actual.

Foreign Investment Promotion Board (FIPB), has cleared the proposal of US-based pharmaceutical firm, Mylan Inc, to acquire Agila Specialties.


The company has proposed to acquire the Indian generic drugs company, Agila Specialties, for Rs 5,168 crore. As per the acquisition, Mylan will acquire the entire issued and outstanding share capital of Agila Specialties, a subsidiary of pharma firm, Strides Arcolab.

The proposal will now have to be approved by the Cabinet Committee on Economic Affairs (CCEA), as it involves investments of more than Rs 1,200 crore.


In July 2013, the proposal of the company had been deferred by FIPB because the Department of Industrial Policy and Promotion (DIPP) had objected, reasoning that it could affect the availability of oncology (cancer-related) injectables which are produced by just a couple of Indian drug makers.


Meanwhile, the board has also cleared another two pending pharmaceutical investment proposals related to brownfield projects. These include a Rs 330 crore investment proposal by Symbiotec Pharmalab, and a proposal by Lotus Surgical Specialties.

← All latest storiesBack to top →